Citations (84)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jonatan Barrera-Chimal, Peter Kolkhof, Ixchel Lima-Posada, Joachim Alexandre, Patrick Rossignol & Frederic Jaisser. (2021) Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. Expert Opinion on Investigational Drugs 30:11, pages 1141-1157.
Read now
Read now
M. Hildebrand, W. Krause, G. Kühne & G.-A. Hoyer. (1987) Pharmacokinetics and metabolism of mespirenone, a new aldosterone antagonist, in rat and cynomolgus monkey. Xenobiotica 17:5, pages 623-634.
Read now
Read now
D. R. Boreham, C. W. Vose, R. F. Palmer, T. F. Slater & K. Cheeseman. (1981) The metabolism of canrenone in vitro by rat liver preparations. Xenobiotica 11:4, pages 231-240.
Read now
Read now
Articles from other publishers (81)
Hana Sutovska, Lubos Molcan, Miroslava Majzunova, Matus Sykora, Libor Kopkan & Michal Zeman. (2023) Mineralocorticoid receptor blockade protects the kidneys but does not affect inverted blood pressure rhythm in hypertensive transgenic (mRen-2)27 rats. Molecular and Cellular Endocrinology 572, pages 111967.
Crossref
Crossref
Ulrich Kintscher, George L. Bakris & Peter Kolkhof. (2022) Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease. British Journal of Pharmacology 179:13, pages 3220-3234.
Crossref
Crossref
R.E. Kast, T.C. Burns & M.-E. Halatsch. (2021) Short review of SEC, a potential dexamethasone-sparing regimen for glioblastoma: Spironolactone, ecallantide, clotrimazole. Neurochirurgie 67:5, pages 508-515.
Crossref
Crossref
Richard E. Kast, Marc-Eric Halatsch & Rafael Rosell. (2021) OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs. Cells 10:5, pages 1148.
Crossref
Crossref
Valter Viana Andrade-Neto, Juliana da Silva Pacheco, Job Domingos Inácio, Elmo Eduardo Almeida-Amaral, Eduardo Caio Torres-Santos & Edezio Ferreira Cunha-Junior. (2021) Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis. Frontiers in Pharmacology 12.
Crossref
Crossref
Prashanth G. Iyer, Stephen G. Schwartz, Jonathan F. Russell & Harry W. Flynn. (2020) Central Serous Chorioretinopathy: Multimodal Imaging and Management Options. Case Reports in Ophthalmological Medicine 2020, pages 1-16.
Crossref
Crossref
Simon Denus, Grégoire Leclair, Marie‐Pierre Dubé, Isabelle St‐Jean, Yassamin Feroz Zada, Essaïd Oussaïd, Martin Jutras, Michael M. Givertz, Robert J. Mentz, W.H. Wilson Tang, João Pedro Ferreira, Jean Rouleau, Javed Butler & Andreas P. Kalogeropoulos. (2020) Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA‐HF trial. European Journal of Heart Failure 22:8, pages 1451-1461.
Crossref
Crossref
Yu-Jing Chiu, Ziwei Zhang, Karolina Dziemidowicz, Christos-Georgios Nikoletopoulos, Ukrit Angkawinitwong, Jiun-Tai Chen & Gareth R. Williams. (2020) The Effect of Solvent Vapor Annealing on Drug-Loaded Electrospun Polymer Fibers. Pharmaceutics 12:2, pages 139.
Crossref
Crossref
David H. Ellison & Shweta Bansal. 2020. Cardiorenal Syndrome in Heart Failure. Cardiorenal Syndrome in Heart Failure
51
71
.
David H. Ellison. (2019) Clinical Pharmacology in Diuretic Use. Clinical Journal of the American Society of Nephrology 14:8, pages 1248-1257.
Crossref
Crossref
Anneli Nordqvist & Kenneth L. Granberg. 2019. Aldosterone. Aldosterone
151
188
.
Paulo W. Pires, Jonathon L. McClain, Sebastian F. Hayoz & Anne M. Dorrance. (2018) Mineralocorticoid receptor antagonism prevents obesity-induced cerebral artery remodeling and reduces white matter injury in rats. Microcirculation 25:5, pages e12460.
Crossref
Crossref
Ehsan Rahimy, John D. PitcherJason HsuMurtaza K. AdamAbtin ShahlaeeWasim A. SamaraJames F. VanderRichard S. KaiserAllen ChiangMarc J. SpirnMitchell S. Fineman. (2018) A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Retina 38:5, pages 962-969.
Crossref
Crossref
Caleb Keng Yan Yip, Sumit Bansal, Siew Ying Wong & Aik Jiang Lau. (2018) Identification of Galeterone and Abiraterone as Inhibitors of Dehydroepiandrosterone Sulfonation Catalyzed by Human Hepatic Cytosol, SULT2A1, SULT2B1b, and SULT1E1. Drug Metabolism and Disposition 46:4, pages 470-482.
Crossref
Crossref
Sabine Huke. (2018) Pannexin Channel Inhibition. Circulation Research 122:4, pages 543-545.
Crossref
Crossref
Miranda E. GoodYu-Hsin ChiuIvan K.H. PoonChristopher B. MedinaJoshua T. ButcherSuresh K. MenduLeon J. DeLalioAlexander W. LohmanNorbert LeitingerEugene BarrettUlrike M. LorenzBimal N. DesaiIris Z. JaffeDouglas A. BaylissBrant E. IsaksonKodi S. Ravichandran. (2018) Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone. Circulation Research 122:4, pages 606-615.
Crossref
Crossref
Peter Kolkhof & Lars Bärfacker. (2017) 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. Journal of Endocrinology 234:1, pages T125-T140.
Crossref
Crossref
Mitja Lainscak, Cristiana Vitale, Petar Seferovic, Ilaria Spoletini, Katja Cvan Trobec & Giuseppe M.C. Rosano. (2016) Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure. International Journal of Cardiology 224, pages 191-198.
Crossref
Crossref
Tyler A. Lanman, Dara Bakar, Nisha M. Badders, Ailbhe Burke, Angela Kokkinis, Joseph A. Shrader, Galen O. Joe, Alice B. Schindler, Laura C. Bott, George G. Harmison, J. Paul Taylor, Kenneth H. Fischbeck & Christopher Grunseich. (2016) Sexual Reassignment Fails to Prevent Kennedy’s Disease. Journal of Neuromuscular Diseases 3:1, pages 121-125.
Crossref
Crossref
Prajakta S. Badri, Jennifer R. King, Akshanth R. Polepally, Barbara H. McGovern, Sandeep Dutta & Rajeev M. Menon. (2015) Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clinical Pharmacokinetics 55:3, pages 275-295.
Crossref
Crossref
Peter Kolkhof, Frederic Jaisser, So-Young Kim, Gerasimos Filippatos, Christina Nowack & Bertram Pitt. 2017. Heart Failure. Heart Failure
271
305
.
Kiyoshi Arai, Hiroyuki Tsuruoka & Tsuyoshi Homma. (2015) CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. European Journal of Pharmacology 769, pages 266-273.
Crossref
Crossref
Domenic A. Sica. (2014) Aldosterone and Volume Management in Hypertensive Heart Disease. Seminars in Nephrology 34:3, pages 323-332.
Crossref
Crossref
Tiffany K. Roberts, Colleen S. Kraft, Deborah French, Wuyang Ji, Alan H.B. Wu, Vin Tangpricha & Corinne R. Fantz. (2014) Interpreting Laboratory Results in Transgender Patients on Hormone Therapy. The American Journal of Medicine 127:2, pages 159-162.
Crossref
Crossref
David H. Ellison. 2013. Seldin and Giebisch's The Kidney. Seldin and Giebisch's The Kidney
1353
1404
.
Carrie A. Northcott, Greg D. Fink, Hannah Garver, Joseph R. Haywood, Erinn L. Laimon-Thomson, Jonathon L. McClain, Paulo W. Pires, William E. Rainey, Christine S. Rigsby & Anne M. Dorrance. (2012) The Development of Hypertension and Hyperaldosteronism in a Rodent Model of Life-Long Obesity. Endocrinology 153:4, pages 1764-1773.
Crossref
Crossref
Peter Kolkhof & Steffen A. Borden. (2012) Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Molecular and Cellular Endocrinology 350:2, pages 310-317.
Crossref
Crossref
Tsuyoshi HOMMA, Michio FUJISAWA, Kiyoshi ARAI, Marie ISHII, Toshio SADA & Masahiro IKEDA. (2012) Spironolactone, but not Eplerenone, Impairs Glucose Tolerance in a Rat Model of Metabolic Syndrome. Journal of Veterinary Medical Science 74:8, pages 1015-1022.
Crossref
Crossref
Juan Pablo Rigalli, María Laura Ruiz, Virginia Gabriela Perdomo, Silvina Stella Maris Villanueva, Aldo Domingo Mottino & Viviana Alicia Catania. (2011) Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells. Toxicology 285:1-2, pages 18-24.
Crossref
Crossref
Kathleen M. Knights, Kushari Bowalgaha & John O. Miners. (2010) Spironolactone and Canrenone Inhibit UGT2B7-Catalyzed Human Liver and Kidney Microsomal Aldosterone 18β-Glucuronidation: A Potential Drug Interaction. Drug Metabolism and Disposition 38:7, pages 1011-1014.
Crossref
Crossref
Mark D. Okusa & David H. Ellison. 2008. Seldin and Giebisch's The Kidney. Seldin and Giebisch's The Kidney
1051
1094
.
Toshiro Niwa, Shinji Honda, Kiyoharu Shirakawa, Yasushi Imamura, Sadayuki Osaki & Akira Takagi. (2006) Drug interaction of fluvoxamine, a selective serotonin reuptake inhibitor. Folia Pharmacologica Japonica 128:2, pages 93-103.
Crossref
Crossref
Ricardo Gómez, Lucía Núñez, Ricardo Caballero, Miguel Vaquero, Juan Tamargo & Eva Delpón. (2005) Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1+minK channels. British Journal of Pharmacology 146:1, pages 146-161.
Crossref
Crossref
Eva Delpón, Ricardo Caballero, Ricardo Gómez, Lucía Núñez & Juan Tamargo. (2005) Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends in Pharmacological Sciences 26:3, pages 155-161.
Crossref
Crossref
Ellen G. McMahon. 2005. Hypertension. Hypertension
736
746
.
Domenic A. Sica. (2005) Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis. Heart Failure Reviews 10:1, pages 23-29.
Crossref
Crossref
F. F. Gudmundsson, A. Viste, O. L. Myking, K. Grong & K. Svanes. (2004) Effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure (IAP) in pigs. Surgical Endoscopy 18:10, pages 1528-1534.
Crossref
Crossref
Susan M Garthwaite & Ellen G McMahon. (2004) The evolution of aldosterone antagonists. Molecular and Cellular Endocrinology 217:1-2, pages 27-31.
Crossref
Crossref
Atsushi Sugiyama, Yoshioki Satoh, Akira Takahara, Kentaro Ando, Kai Wang, Sachiko Honsho, Yuji Nakamura & Keitaro Hashimoto. (2004) Electropharmacological Effects of a Spironolactone Derivative, Potassium Canrenoate, Assessed in the Halothane-Anesthetized Canine Model. Journal of Pharmacological Sciences 96:4, pages 436-443.
Crossref
Crossref
Stefan Viktor Vormfelde, Gerhard Burckhardt, Alexandra Zirk, Leszek Wojnowski & Jürgen Brockmöller. (2003) Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 4:6, pages 701-734.
Crossref
Crossref
R. Caballero. (2003) Spironolactone and Its Main Metabolite, Canrenoic Acid, Block Human Ether-a-Go-Go-Related Gene Channels. Circulation 107:6, pages 889-895.
Crossref
Crossref
Chyung S. Cook, Loren M. Berry, David H. Kim, Earl G. Burton, Jeremy D. Hribar & Liming Zhang. (2002) Involvement of CYP3A in the Metabolism of Eplerenone in Humans and Dogs: Differential Metabolism by CYP3A4 and CYP3A5. Drug Metabolism and Disposition 30:12, pages 1344-1351.
Crossref
Crossref
Françoise Rougé‐Pont, Djoher Nora Abrous, Michel Le Moal & Pier Vincenzo Piazza. (2008) Release of endogenous dopamine in cultured mesencephalic neurons: influence of dopaminergic agonists and glucocorticoid antagonists. European Journal of Neuroscience 11:7, pages 2343-2350.
Crossref
Crossref
W.H. Ong, J.P. Guignard, A. Sharma & J.V. Aranda. (1998) Pharmacological approach to the management of neonatal hypertension. Seminars in Neonatology 3:2, pages 149-161.
Crossref
Crossref
Garabed Eknoyan. 1997. Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS. Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS
489
511
.
D. Craig Brater. 1997. Diuretic Agents. Diuretic Agents
189
208
.
Pier Vincenzo Piazza, Michel Barrot, Françoise Rougé-Pont, Michela Marinelli, Stefania Maccari, Djoher Nora Abrous, Hervé Simon & Michel Le Moal. (1996) Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. Proceedings of the National Academy of Sciences 93:26, pages 15445-15450.
Crossref
Crossref
V Arroyo, P Ginès, A L Gerbes, F J Dudley, P Gentilini, G Laffi, T B Reynolds, H Ring-Larsen & J Schölmerich. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23:1, pages 164-176.
Crossref
Crossref
Ina Sungaila, William R. Bartle, Scott E. Walker, Carlo DeAngelis, Jack Uetrecht, Chris Pappas & Eva Vidins. (1992) Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 102:5, pages 1680-1685.
Crossref
Crossref
France Varin, The Minh Tu, France Benoît, Jean-Pierre Villeneuve & Yves Théorêt. (1992) High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction. Journal of Chromatography B: Biomedical Sciences and Applications 574:1, pages 57-64.
Crossref
Crossref
David B. JackDavid B. Jack. 1992. Handbook of Clinical Pharmacokinetic Data. Handbook of Clinical Pharmacokinetic Data
84
88
.
Peter D.A. Crosby & Roger S. Rittmaster. (1991) Predictors of clinical response in hirsute women treated with spironolactone. Fertility and Sterility 55:6, pages 1076-1081.
Crossref
Crossref
Günter SeyffartGünter Seyffart. 1991. Drug Dosage in Renal Insufficiency. Drug Dosage in Renal Insufficiency
527
557
.
Garabed Eknoyan. 1990. Therapy of Renal Diseases and Related Disorders. Therapy of Renal Diseases and Related Disorders
425
441
.
Sylvain Chemtob, Bernard S. Kaplan, Joseph R. Sherbotie & Jacob V. Aranda. (1989) Pharmacology of Diuretics in the Newborn. Pediatric Clinics of North America 36:5, pages 1231-1250.
Crossref
Crossref
Peter Gardiner, Kathy Schrode, David Quinlan, Bernard K. Martin, Donald R. Boreham, Maurice S. Rogers, Katherine Stubbs, Margaret Smith & Aziz Karim. (2013) Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing Metabolites. The Journal of Clinical Pharmacology 29:4, pages 342-347.
Crossref
Crossref
Aldo D. Mottino, Edgardo E. Guibert & Emilio A.Rodríguez Garay. (1989) Additive effect of combined spironolactone and phenobarbital treatment on hepatic bilirubin UDP-glucuronyltransferase. Biochemical Pharmacology 38:5, pages 851-853.
Crossref
Crossref
Charles S. Markos, Clifford R. Dorn & Donald J. Zitzewitz. (2006) Synthesis of canrenone and related steroids labelled with tritium, carbon‐14, and sulfur‐35. Journal of Labelled Compounds and Radiopharmaceuticals 25:5, pages 515-529.
Crossref
Crossref
R. G. Morris, D. B. Frewin, W. B. Taylor, M. L. Glistak & D. R. Lehmann. (1988) The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays. European Journal of Clinical Pharmacology 34:3, pages 233-239.
Crossref
Crossref
John R. Cashman & Sandra Pena. (1988) S-OXYGENATION OF 7α-THIOMETHYLSPIRONOLACTONE BY THE FLAVIN-CONTAINING MONOOXYGENASE. Drug Metabolism and Drug Interactions 6:3-4.
Crossref
Crossref
James H. Sherry, Peggy B. Johnson & Howard D. Colby. (1988) Species differences in adrenal spironolactone metabolism: relationship to cytochrome P-450 destruction. Biochemical Pharmacology 37:2, pages 355-357.
Crossref
Crossref
H.W.P.M. Overdiek & F.W.H.M. Merkus. (1987) THE METABOLISM AND BIOPHARMACEUTICS OF SPIRONOLACTONE IN MAN. Drug Metabolism and Drug Interactions 5:4, pages 273-302.
Crossref
Crossref
M. Hildebrand & s. Schütt. (1987) Column liquid chromatography of the novel aldosterone antagonist, mespirenone, and its active metabolite in plasma. Journal of Chromatography B: Biomedical Sciences and Applications 414, pages 217-222.
Crossref
Crossref
James H. Sherry, John P. O'Donnell & Howard D. Colby. (1986) Separation of spironolactone and its biologically active sulfur-containing metabolites by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 374, pages 183-190.
Crossref
Crossref
Björn Beermann. (2009) Aspects on pharmacokinetics of some diuretics. Acta Pharmacologica et Toxicologica 54, pages 17-29.
Crossref
Crossref
Bo Odlind. (2009) Site and mechanism of the action of diuretics. Acta Pharmacologica et Toxicologica 54, pages 5-15.
Crossref
Crossref
J. Greven & O. Heidenreich. 1984. Pharmacology of Antihypertensive Drugs. Pharmacology of Antihypertensive Drugs
66
101
.
P. C. Ho, D. W. A. Bourne, E. J. Triggs & V. Heazlewood. (1984) Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. European Journal of Clinical Pharmacology 27:4, pages 441-446.
Crossref
Crossref
P. C. Ho, D. W. A. Bourne, E. J. Triggs & B. A. Smithurst. (1984) Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone. European Journal of Clinical Pharmacology 27:4, pages 435-439.
Crossref
Crossref
William A. Briggs, Franklin D. McDonald, Dale M. Sillix & Margaret L. MacDougall. 1984. Therapy of Renal Diseases and Related Disorders. Therapy of Renal Diseases and Related Disorders
567
586
.
Garabed Eknoyan. 1984. Therapy of Renal Diseases and Related Disorders. Therapy of Renal Diseases and Related Disorders
283
296
.
William M. Bennett, George R. Aronoff, Gail Morrison, Thomas A. Golper, Joseph Pulliam, Marsha Wolfson & Irwin Singer. (1983) Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. American Journal of Kidney Diseases 3:3, pages 155-193.
Crossref
Crossref
U. Weissenborn & H.C. Erbler. (1983) Metabolism of spirolactones by the rat testis in vitro. Steroids 42:4, pages 365-388.
Crossref
Crossref
A. J. Nijkerk, J. M. Vermeer, M. Imanse & D. de Vos. (1983) The bioavailability of two new preparations of spironolactone tablets. Pharmaceutisch Weekblad 5:5, pages 210-212.
Crossref
Crossref
R.M. Pérez-Ayuso, V. Arroyo, R. Planas, J. Gaya, F. Bory, A. Rimola, F. Rivera & J. Rodés. (1983) Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Gastroenterology 84:5, pages 961-968.
Crossref
Crossref
MD Fernandez, GD Carter & TN Palmer. (2012) The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.. British Journal of Clinical Pharmacology 15:1, pages 95-101.
Crossref
Crossref
Jacob V. Aranda & Leo Stern. (1983) Clinical aspects of developmental pharmacology and toxicology. Pharmacology & Therapeutics 20:1, pages 1-51.
Crossref
Crossref
J. D. Fitzgerald. 1983. Care of the Critically Ill Patient. Care of the Critically Ill Patient
261
308
.
James H. Sherry, John P. O'Donnell & Howard D. Colby. (1981) Conversion of spironolactone to an active metabolite in target tissues: formation of 7α-thiospironolactone by microsomal preparations from guinea pig liver, adrenals, kidneys, and testes. Life Sciences 29:26, pages 2727-2736.
Crossref
Crossref
U. Abshagen, D. Platt & H. -J. Horn. (1981) Zur Pharmakokinetik von Spironolacton im AlterOn the pharmacokinetics of spironolactone in the elderly. Klinische Wochenschrift 59:16, pages 909-910.
Crossref
Crossref
GT McInnes, MJ Asbury, JR Shelton, IR Harrison, LE Ramsay, GR Venning & JM Clarke. (2012) The active constituent of spironolactone after acute administration in man [proceedings]. British Journal of Clinical Pharmacology 9:3.
Crossref
Crossref